Skip to main content
IO Biotech, Inc. logo

IO Biotech, Inc. — Investor Relations & Filings

Ticker · IOBT ISIN · US4497781090 US Manufacturing
Open in API
Filings indexed 265 across all filing types
Latest filing 2026-03-31 Board/Management Inform…
Country US United States of America
Listing US IOBT

About IO Biotech, Inc.

https://www.iobiotech.com/

IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing novel, immune-modulatory therapeutic cancer vaccines. The company's proprietary T-win technology platform is engineered to create dual-action vaccines that activate the patient's T cells to simultaneously target and eliminate both cancer cells and immune-suppressive cells within the tumor microenvironment. These off-the-shelf therapies are intended to improve outcomes for patients with various solid tumors. The lead product candidate, Cylembio® (IO102-IO103), is being evaluated in clinical trials for melanoma and other cancers, while additional pipeline candidates are in preclinical development.

Recent filings

Filing Released Lang Actions
8-K - IO Biotech, Inc. (0001865494) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 31, 2026. It reports significant corporate events including the company's filing for Chapter 7 bankruptcy, resignation of all board members, termination of officers, and the inability to complete the audit or file the Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The content focuses on management changes and significant corporate events rather than financial results or detailed financial statements. The primary focus is on the departure of directors and officers due to bankruptcy and related corporate governance changes. Therefore, the document best fits the category of Board/Management Information (MANG).
2026-03-31 English
8-K Filing
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 12, 2026, by IO Biotech, Inc. It reports receipt of a notice from Nasdaq regarding non-compliance with the continued listing requirements due to the market value of listed securities being below the minimum threshold. The document discusses the potential delisting process and compliance timeline but does not contain financial statements or detailed financial data. The primary content is an official notice about the company's stock potentially being delisted from Nasdaq. Given the focus on delisting and the nature of the announcement, this fits the category of a Delisting Announcement (DLST). The document length is 4182 characters, which is consistent with a detailed announcement rather than a brief notice or a full report. Therefore, the classification is DLST with high confidence.
2026-02-13 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-13 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-06 English
8-K Filing
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes a restructuring and workforce reduction plan, departure of a named executive officer, and retention of a financial advisor for strategic alternatives. There are no financial statements or detailed financial data presented, only announcements of corporate events and plans. The document is not an annual or quarterly report, nor is it a transcript or presentation. It is a regulatory filing reporting significant corporate events and changes, fitting the category of Regulatory Filings (RNS).
2026-01-30 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-01-23 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.